北美疫苗佐剂市场预测至 2030 年 – 区域分析 – 按佐剂类别（矿物盐佐剂、乳液佐剂、脂质体佐剂等）和类型（人用疫苗佐剂和兽用疫苗佐剂）
传染病爆发和大流行数量增加推动北美疫苗佐剂市场发展
根据世界银行 2023 年的报告，细菌、病毒、寄生虫或真菌疾病具有传染性，可直接在人与人或动物与人之间传播。根据美国国立卫生研究院 (NIH) 的报告，H1N1 流感大流行给墨西哥旅游业造成约 28 亿美元的损失，因为在 H1N1 病毒传染性传播的 5 个月内，游客人数减少了近 100 万。 2024 年 3 月，墨西哥特斯科科州报告了一起低致病性禽流感 (LPAI) A(H5N2) 疫情，该州的特马斯卡拉帕市在 4 月报告了另一起疫情。此外，在米却肯州，一家私人家禽养殖场发现了一起高致病性禽流感 A(H5N2) 疫情，该疫情于 2024 年 3 月发现。2022 年，据报道，最近和过去，墨西哥的鸟类中都发现了 LPAI 和 HPAI A(H5) 亚型。虽然动物流感病毒通常会感染动物，但它们也会感染人。人类感染大多是通过与受感染或受污染环境的动物密切接触而感染的。甲型流感病毒可根据其原始宿主分为禽流感、猪流感或其他动物流感病毒。因此，各种传染病的出现及其相关的成本负担加速了制造商对疫苗和疫苗佐剂的需求。
COVAXIN 是 Bharat Biotech 为抗击 COVID-19 大流行而开发的疫苗，它使用 Alhydroxiquim-II 作为佐剂。生物技术公司 ViroVax LLC 在实验室中发现并测试了这种佐剂。Alhydroxiquim-II 的药理作用是它穿过淋巴结并激活 TLR7 和 TLR8 细胞受体，这在对抗病毒的免疫反应中起着至关重要的作用。Alhydroxiquim-II 是第一个负责激活 TLR7 和 TLR8 的佐剂，从而刺激人们的免疫反应。因此，传染病爆发和大流行的数量不断增加，导致医疗成本高昂，推动了对疫苗佐剂的需求。
北美疫苗佐剂市场概览
北美疫苗佐剂市场已细分为美国、加拿大和墨西哥。快速的产品审批流程使美国的疫苗佐剂市场受益。2023 年 5 月，葛兰素史克 (GSK) 的 Arexvy（呼吸道合胞病毒疫苗，佐剂）疫苗获得美国食品药品监督管理局 (FDA) 批准，用于预防呼吸道合胞病毒 (RSV) 引起的下呼吸道疾病 (LRTD)。因此，Arexvy 成为世界上第一个获得 FDA 批准的老年人 RSV 疫苗。2022 年 10 月，Novavax, Inc. 获得了 FDA 对其 COVID-19 佐剂疫苗的紧急使用授权 (EUA)，该疫苗适用于成人患者的加强剂。
北美疫苗佐剂市场收入及预测至 2030 年（百万美元）
北美疫苗佐剂市场细分
北美疫苗佐剂市场分为佐剂类别、类型和国家。
根据佐剂类别，北美疫苗佐剂市场细分为矿物盐佐剂、乳剂佐剂、脂质体佐剂等。矿物盐佐剂部分在 2022 年占据北美疫苗佐剂市场份额的最大份额。
按类型，北美疫苗佐剂市场分为人用疫苗佐剂和兽用疫苗佐剂。 2022 年，人用疫苗佐剂部分占据了北美疫苗佐剂市场的较大份额。
按国家/地区划分，北美疫苗佐剂市场分为美国、加拿大和墨西哥。2022 年，美国占据了北美疫苗佐剂市场份额的主导地位。
Croda International Plc；CSL Ltd；Dynavax Technologies Corp；GSK Plc；Hawaii Biotech Inc；InvivoGen SAS；Novavax Inc；Phibro Animal Health Corp；Seppic SA；和 SPI Pharma Inc 是北美疫苗佐剂市场的一些领先公司。
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Vaccine Adjuvants Market – Key Market Dynamics
4.1 North America Vaccine Adjuvants Market – Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Number of Infectious Disease Outbreaks and Pandemic
4.2.2 Approvals of Veterinary Vaccine Adjuvants
4.3 Market Restraints
4.3.1 Product Recalls and Adverse Effects
4.4 Market Opportunities
4.4.1 Support for Developments in Adjuvant Studies and Collaborative Efforts for Product Launches
4.4.2 Advancements in Biotechnology and Immunology
4.5 Future Trends
4.5.1 Technological Advancements
4.6 Impact of Drivers and Restraints:
5. Vaccine Adjuvants Market –North America Analysis
5.1 North America Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
5.2 North America Vaccine Adjuvants Market Forecast and Analysis
6. North America Vaccine Adjuvants Market Analysis – by Adjuvant Class
6.1 Overview
6.2 Mineral Salt Adjuvant
6.2.1 Overview
6.2.2 Mineral Salt Adjuvant: North America Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.3 Emulsion Adjuvant
6.3.1 Overview
6.3.2 Emulsion Adjuvant: North America Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Liposome Adjuvant
6.4.1 Overview
6.4.2 Liposome Adjuvant: North America Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Others
6.5.1 Overview
6.5.2 Others: North America Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7. North America Vaccine Adjuvants Market Analysis – by Type
7.1 Human Vaccine Adjuvant
7.1.1 Overview
7.1.2 Human Vaccine Adjuvant: North America Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.2 Veterinary Vaccine Adjuvant
7.2.1 Overview
7.2.2 Veterinary Vaccine Adjuvant: North America Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8. North America Vaccine Adjuvants Market –Country Analysis
8.1 North America
8.1.1 North America Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
8.1.1.1 United States: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.1.1 Overview
8.1.1.1.2 United States: Glucose Monitoring Devices Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.1.3 United States: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.1.4 United States: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.2 Canada: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.2.1 Overview
8.1.1.2.2 Canada: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.2.3 Canada: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.2.4 Canada: Vaccine Adjuvants Market Breakdown, by Type
8.1.1.3 Mexico: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.3.1 Overview
8.1.1.3.2 Mexico: Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.1.1.3.3 Mexico: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
8.1.1.3.4 Mexico: Vaccine Adjuvants Market Breakdown, by Type
9. Industry Landscape
9.1 Overview
9.2 Growth Strategies in the Global Vaccine Adjuvants Market
9.3 Organic Developments
9.3.1 Overview
9.4 Inorganic Developments
9.4.1 Overview
10. Company Profiles
10.1 SPI Pharma Inc
10.1.1 Key Facts
10.1.2 Business Description
10.1.3 Products and Services
10.1.4 Financial Overview
10.1.5 SWOT Analysis
10.1.6 Key Developments
10.2 GSK Plc
10.2.1 Key Facts
10.2.2 Business Description
10.2.3 Products and Services
10.2.4 Financial Overview
10.2.5 SWOT Analysis
10.2.6 Key Developments
10.3 CSL Ltd
10.3.1 Key Facts
10.3.2 Business Description
10.3.3 Products and Services
10.3.4 Financial Overview
10.3.5 SWOT Analysis
10.3.6 Key Developments
10.4 Seppic SA
10.4.1 Key Facts
10.4.2 Business Description
10.4.3 Products and Services
10.4.4 Financial Overview
10.4.5 SWOT Analysis
10.4.6 Key Developments
10.5 Hawaii Biotech Inc
10.5.1 Key Facts
10.5.2 Business Description
10.5.3 Products and Services
10.5.4 Financial Overview
10.5.5 SWOT Analysis
10.5.6 Key Developments
10.6 Dynavax Technologies Corp
10.6.1 Key Facts
10.6.2 Business Description
10.6.3 Products and Services
10.6.4 Financial Overview
10.6.5 SWOT Analysis
10.6.6 Key Developments
10.7 InvivoGen SAS
10.7.1 Key Facts
10.7.2 Business Description
10.7.3 Products and Services
10.7.4 Financial Overview
10.7.5 SWOT Analysis
10.7.6 Key Developments
10.8 Croda International Plc
10.8.1 Key Facts
10.8.2 Business Description
10.8.3 Products and Services
10.8.4 Financial Overview
10.8.5 SWOT Analysis
10.8.6 Key Developments
10.9 Novavax Inc
10.9.1 Key Facts
10.9.2 Business Description
10.9.3 Products and Services
10.9.4 Financial Overview
10.9.5 SWOT Analysis
10.9.6 Key Developments
10.10 Phibro Animal Health Corp
10.10.1 Key Facts
10.10.2 Business Description
10.10.3 Products and Services
10.10.4 Financial Overview
10.10.5 SWOT Analysis
10.10.6 Key Developments
11. Appendix
11.1 About The Insight Partners
List of Tables
Table 1. North America Vaccine Adjuvants Market Segmentation
Table 2. North America Vaccine Adjuvants Market Revenue and Forecasts To 2030 (US$ Million)
Table 3. United States: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 4. United States: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 5. Canada: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 6. Canada: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 7. Mexico: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Adjuvant Class
Table 8. Mexico: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 9. Organic Developments Done by Companies
Table 10. Inorganic Developments Done by Companies
List of Figures
Figure 1. North America Vaccine Adjuvants Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. North America Vaccine Adjuvants Market Revenue (US$ Million), 2022–2030
Figure 4. North America Vaccine Adjuvants Market Share (%) – by Adjuvant Class (2022 and 2030)
Figure 5. Mineral Salt Adjuvant: North America Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 6. Emulsion Adjuvant: North America Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Liposome Adjuvant: North America Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: North America Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. North America Vaccine Adjuvants Market Share (%) – by Type (2022 and 2030)
Figure 10. Human Vaccine Adjuvant: North America Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Veterinary Vaccine Adjuvant: North America Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. North America Vaccine Adjuvants Market by Key Countries – Revenue (2022) US$ Million
Figure 13. North America Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 14. United States: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 15. Canada: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 16. Mexico: Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 17. Growth Strategies in the Vaccine Adjuvants Market
- Croda International Plc
- CSL Ltd
- Dynavax Technologies Corp
- GSK Plc
- Hawaii Biotech Inc
- InvivoGen SAS
- Novavax Inc
- Phibro Animal Health Corp
- Seppic SA
- SPI Pharma Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America vaccine adjuvants market.
- Highlights key business priorities to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America vaccine adjuvants market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.